Prasugrel is a P2Y12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI). MedsAcross supplies Prasugrel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows: Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI.
Source: US FDA prescribing information
Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP receptors on platelets.
Source: US FDA prescribing information
Initiate Effient treatment as a single 60 mg oral loading dose and then continue at 10 mg orally once daily. Patients taking Effient should also take aspirin (75 mg to 325 mg) daily. Effient may be administered with or without food. Initiate treatment with a single 60 mg oral loading dose. Continue at 10 mg once daily with or without food. Consider 5 mg once daily for patients <60 kg. Patients should also take aspirin (75 mg to 325 mg) daily. Timing of Loading Dose In the clinical trial that established the efficacy and safety of Effient, the loading dose of Effient was not administered until coronary anatomy was established in UA/NSTEMI patients and in STEMI patients presenting more than 12 hours after symptom onset.
Source: US FDA prescribing information
Active pathological bleeding. Prior transient ischemic attack or stroke. Hypersensitivity to prasugrel or any component of the product
Source: US FDA prescribing information
Boxed warning (bleeding risk): Effient can cause significant, sometimes fatal, bleeding. Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack (TIA) or stroke. CABG-related bleeding: Risk increases in patients receiving Effient who undergo CABG. Discontinuation of Effient: Premature discontinuation increases risk of stent thrombosis, MI, and death. Thrombotic thrombocytopenic purpura (TTP): TTP has been reported with Effient. Hypersensitivity: Hypersensitivity including angioedema has been reported with Effient including in patients with a history of hypersensitivity reaction to other thienopyridines.
Source: US FDA prescribing information
The following serious adverse reactions are also discussed elsewhere in the labeling: Bleeding Thrombotic Thrombocytopenic Purpura Hypersensitivity Including Angioedema Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction.
Source: US FDA prescribing information
Opioids: Decreased exposure to prasugrel. Consider use of parenteral antiplatelet agent. Warfarin Coadministration of Effient and warfarin increases the risk of bleeding.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Prasugrel, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Prasugrel 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Prasugrel 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Effient 10 mg tabletOral | Cosette Pharmaceuticals | US FDA | Available on request |
| Effient 5 mg tabletOral | Cosette Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Prasugrel in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Prasugrel and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Prasugrel, including Effient.
Yes. The US FDA first approved Prasugrel on 10 July 2009, according to Drugs@FDA.
Yes. Prasugrel has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Prasugrel is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Prasugrel is classified under ATC code B01AC22 (Prasugrel).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.